featured-image

, /PRNewswire/ -- (Nasdaq: ) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase , proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy. The data are being presented at SLEEP 2024, the 38 annual meeting of the Associated Professional Sleep Societies (APSS), taking place in . The phase study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of ALKS 2680 via once-daily, single, oral administration.

Ten patients with NT1 were randomized to one of four crossover sequences in which each participant received 1 mg, 3 mg and 8 mg of ALKS 2680, and placebo, with washout periods between each treatment. Initial results from the first four patients in this NT1 cohort were previously presented at the 2023 World Sleep Congress. "Data from this phase study provide evidence of a significant treatment effect of single doses of ALKS 2680 in patients with narcolepsy type 1.



In addition, patients' self-reported measures of alertness further support continued clinical development of this investigational treatment, which has the potential to help address significant unmet needs for people living with excessive daytime sleepiness associated with narcolepsy," said , M.D., Ph.

D., Head of Sleep and Circadian Research at the Woolcock Institute of Medical Research. Data highlights from the SLEEP poster presentation (Abstract ID 1.

Back to Health Page